These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30921591)

  • 21. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
    Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
    Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C eradication: A long way to go.
    Waheed Y
    World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.
    Bertisch B; Giudici F; Negro F; Moradpour D; Müllhaupt B; Moriggia A; Estill J; Keiser O;
    PLoS One; 2016; 11(5):e0155464. PubMed ID: 27227332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    Gountas I; Sypsa V; Blach S; Razavi H; Hatzakis A
    PLoS One; 2018; 13(8):e0202109. PubMed ID: 30114207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Find the Missing Millions: Malaysia's experience with nationwide hepatitis C screening campaign in the general population.
    Md Said R; Mohd Zain R; Chan HK; Soelar SA; Rusli N; Nasir NH; Zakaria R; Hassan MRA
    J Viral Hepat; 2020 Jun; 27(6):638-643. PubMed ID: 31997563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    Mooneyhan E; Qureshi H; Mahmood H; Tariq M; Maqbool NA; Anwar M; Aslam M; Azam F; Blach S; Khan AG; Hamid S; Hussain T; Akhter MK; Khan A; Khan U; Khowaja S; Mahmood K; Mazhar S; Nawaz A; Rose A; Ghorezai GSA; Shah S; Sarwar SZ; Razavi H
    J Viral Hepat; 2023 Apr; 30(4):345-354. PubMed ID: 36650932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project.
    Dröse S; Øvrehus ALH; Holm DK; Madsen LW; Mössner BK; Søholm J; Hansen JF; Røge BT; Christensen PB
    BMC Infect Dis; 2022 Mar; 22(1):202. PubMed ID: 35232372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary.
    Kondili LA; Aghemo A; Andreoni M
    Ann Ist Super Sanita; 2021; 57(3):201-204. PubMed ID: 34554113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: Strategies, results, and costs.
    Turner BJ; Taylor BS; Hanson JT; Perez ME; Hernandez L; Villarreal R; Veerapaneni P; Fiebelkorn K
    J Hosp Med; 2015 Aug; 10(8):510-6. PubMed ID: 26033458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.
    Hasan F; Alfadhli A; Al-Gharabally A; Alkhaldi M; Colombo M; Lazarus JV
    World J Gastroenterol; 2020 Aug; 26(30):4415-4427. PubMed ID: 32874054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-care testing for HCV infection: recent advances and implications for alternative screening.
    Parisi MR; Soldini L; Vidoni G; Mabellini C; Belloni T; Brignolo L; Negri S; Schlusnus K; Dorigatti F; Lazzarin A
    New Microbiol; 2014 Oct; 37(4):449-57. PubMed ID: 25387283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?
    Darke J; Cresswell T; McPherson S; Hamoodi A
    J Public Health (Oxf); 2016 Dec; 38(4):e554-e562. PubMed ID: 28158850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.